Prohost Comprehensive Letter #451
Shorting Biotech Firms with Solid Fundamentals

Unfair shorting of promising stocks seems to have become the norm during the harsh circumstances that not only the United States but several other countries have been living under for more than two years.

The bad circumstances in the United States seem to be motivating unfair short-sellers to take advantage of bad news and cause huge selloffs of clinical-stage biotechnology firms’ stocks, including Prohost picked small clinical-stage firms. The shorters have indeed . . .